Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
about
Improved endpoints for cancer immunotherapy trialsAnti-cancer vaccines - a one-hit wonder?Evaluation of current cancer immunotherapy: hemato-oncologyImmune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disordersDNA vaccine for cancer immunotherapyActive idiotypic vaccination versus control immunotherapy for follicular lymphomaInduction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationTumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.Translating tumor antigens into cancer vaccinesIdiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Haematological malignancies: at the forefront of immunotherapeutic innovation.Therapeutic cancer vaccines: current status and moving forward.Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulinsTrial watch: Peptide vaccines in cancer therapyDendritic cell vaccination in glioblastoma after fluorescence-guided resectionTrial watch: DNA vaccines for cancer therapy.CD28 aptamers as powerful immune response modulatorsSuccesses, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.Artificial antigen-presenting cells for use in adoptive immunotherapy.Idiotype vaccine strategies for treatment of follicular lymphoma.Idiotype vaccines for lymphoma therapy.Vaccination strategies in lymphomas and leukaemias: recent progress.CAR T cells: driving the road from the laboratory to the clinic.Peptide vaccines for hematological malignancies: a missed promise?Antigen-specific vaccines for cancer treatment.In situ vaccination for the treatment of cancer.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model.The promise of the anti-idiotype concept.BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.
P2860
Q24603112-5D0BA490-84EA-438B-A4F2-7617355392FAQ26995164-700CB8E5-148C-4244-944A-3B39AA6ADEF3Q27006179-3F8B3557-E031-4FC3-8AAA-580B5C60BE49Q27491280-917D6B25-75D3-483E-96C1-60D05428EFAEQ28080919-D300DA42-D5BA-4396-8F9F-B9EA1F49A28FQ33691505-8B9977B8-95BA-4DD0-A778-D11546E8780FQ34068404-AFC07FE9-BE84-47F8-8AFD-CC8BDDB09A8AQ34097414-749BEE44-6F3C-4019-80A1-2DD5618AFB70Q34484042-17706CAE-D4DB-4902-B56B-DA1BA57C3556Q35113388-2C6E68E1-A5D3-4348-A5FB-BE8BEE2EB2C6Q35880618-0FE20BAB-2194-4F5B-AC58-853C311C57B8Q35894347-D18C425A-D183-4070-8499-D282FD026595Q35928330-A7AE0D78-93EE-4BD6-A2AC-0A7400FF1404Q36074726-7B77E0E2-4462-44CC-9CEB-7A9B4FC8E527Q36386109-F862F76B-9CC7-4487-A8BE-177CD2DB6721Q36476100-1AAEA27F-D5EF-4896-B694-1FD92A99AF2FQ36507978-168D58BA-609B-4489-816E-0BE67DDAE0D0Q36845824-C4F779BE-BE03-4E40-B0E3-66B208B1D2D1Q36968197-298A67AE-EE6F-4C1F-AC32-04CB0DFE8127Q37505384-3946838E-A9D0-417C-AA33-532460241FE3Q37778699-4E00EE03-E51A-4CFA-B32E-2389B02D3353Q37822740-3F95162D-1457-4024-A51D-28599C5C2B55Q37892587-E2A488F9-D67E-49B9-8D22-BA52501CE17FQ37929157-56FD0693-7DB1-436D-815B-DFC3D2B576ADQ38170499-E580A00A-AD0A-4DCB-9826-1F57961A0303Q38176546-17FCB3BD-DED9-4897-91A2-2E2CB66E3032Q38284692-F2042479-4E8E-4EB6-8EE9-D498D3607A81Q38727470-469C9D02-5523-4D64-911F-26DF478FDE16Q38843235-9005EB2D-32F4-45B2-959E-3B94F06D13A5Q38974216-DC421295-6F05-4077-8AA5-3991B83F2229Q39043404-D476E690-6B8F-4CC7-A504-22C96BD226BDQ39066916-0E4BB234-08D7-4E79-A166-D81214D5A8CEQ39527856-9E9AA180-79B2-4EC7-B17C-A2597F72752DQ39750020-9A49D825-9989-4F14-9C29-53D82664DD3BQ42140467-436C2C28-98DF-4868-848F-372862FB7D88Q42215347-FBE3C060-AA63-491B-AFB5-7DF47D1713F2Q42260317-989ECE2D-9D4C-4F14-ABC0-43E5D556DD13Q42419120-7979C40C-CDA2-418C-ADCD-1065AA47DC79Q43905270-6BDE55D4-24E5-4AFB-944C-1C7973A3FB01Q47133741-4A71E1C3-6155-49AF-8A53-AC32DFDEB7C7
P2860
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@en
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@nl
type
label
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@en
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@nl
prefLabel
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@en
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@nl
P356
P1476
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
@en
P2093
Maurizio Bendandi
P2888
P304
P356
10.1038/NRC2717
P407
P577
2009-09-01T00:00:00Z